The global anatomic pathology market was valued at USD 30.16 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. This growth is largely driven by the increasing use of biomarkers in clinical settings, which provide pathologists with insights into molecular-level mechanisms. These insights play a crucial role in clinical decision-making, ultimately improving patient outcomes. As a result, pathology tests and procedures based on biomarkers are being increasingly used to study common cancers and the processes behind tumor development. The growing reliance on biomarker-based pathology is expected to further fuel the market's expansion.
Additionally, the increasing adoption of advanced pathology equipment—such as digital microscopes, gross imaging systems, and staining systems—is expected to significantly improve anatomic pathology practices. Among these, digital imaging solutions offer superior specificity and accuracy compared to traditional methods. This enhanced diagnostic precision and reliability is leading to a growing demand for such technologies in the anatomic pathology market, contributing to its overall growth.
Gather more insights about the market drivers, restrains and growth of the Anatomic Pathology Market
Product Services Segmentation Insights
In 2022, the consumables segment held the largest share of the market, accounting for 69.1% of the total revenue. This dominance is driven by several factors, including the widespread availability and affordability of pathology consumables. The market's expansion is further supported by the accessibility of a wide variety of products in this segment. A diverse range of essential reagents, antibodies, and probes, specifically designed for anatomic pathology procedures, is available for purchase. Key examples include products like the ultra-view SISH DNP Detection Kit, the Instrument Cleaning Kit from Agilent, the Tamping Tools KitsISH iVIEW Blue Plus Detection Kit from F. Hoffmann-La Roche Ltd, and the CISH Centromere Detection Kits from Thermo Fisher. In May 2023, Sysmex introduced its Clinical Flow Cytometry1 System in Japan, as well as other antibody reagents like the Sample Preparation System PS-10 in regions including Asia Pacific and North America.
This launch contributes to higher efficiency and the improvement of testing standards and strategies. Additionally, in September 2022, F. Hoffmann-La Roche Ltd launched the PRAME (EPR20330) antibody, which measures PRAME protein expression and aids in diagnosing melanoma through tissue sampling.
The instruments segment is expected to grow at the fastest rate, with a CAGR of 9.6% from 2023 to 2030. This rapid growth is fueled by ongoing technological innovations and efforts by market participants to develop advanced anatomic pathology instruments. For example, in March 2023, Virscio, Inc. established a new Pathology and Tissue Pharmacodynamics Division to enhance its preclinical drug development capabilities. This strategic initiative aims to improve the efficiency, impact, and overall success of preclinical drug development programs by strengthening the company's expertise in pathology and tissue pharmacodynamics. Additionally, in April 2020, Precision Instruments launched its CF-6100 cryostat, designed to support tissue sectioning in histology, pathology, and dermatology practices. These advancements are expected to further drive the growth of the instruments segment during the forecast period.
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
